Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

Recruiting Phase 2 Interventional Study
Fuchs Endothelial Corneal Dystrophy
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
21 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
45 (estimated)
Sponsor
Massachusetts Eye and Ear Infirmary · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Male or female ≥21 years of age at time of surgical evaluation. 2. Diagnosis of advanced FECD and visually significant cataract 3. Indication for DMEK (Descemet Membrane Endothelial Keratoplasty) with concurrent cataract surgery 4. Written informed consent obtained from subje…
Contacts

Michael Cheung, MSc, CCRP

6175736060

mcheung0@meei.harvard.edu

CONTACT

Ula Jurkunas, MD

617-573-4330

Ula_Jurkunas@meei.harvard.edu

CONTACT